BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Elaheh Kordzadeh-Kermani, Hossein Khalili, Iman Karimzadeh, Mohammadreza Salehi. <p>Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators</p>Infection and Drug Resistance 2020; : 513 doi: 10.2147/IDR.S233137
2
Yu Shi, Min Zheng. Hepatitis B virus persistence and reactivationBMJ 2020; : m2200 doi: 10.1136/bmj.m2200
3
Leonardo Calle García, Pilar Tajada Alegre, Victoria M. Villalta Robles, Ana Avellón Calvo, M. Astrid Rodríguez Gómez, Manuel Heras Benito, Rebeca Amo Alonso, Carmen Martín Varas, Giomar Urzola Rodríguez, M. José Fernández-Reyes Luis. Reactivación silenciosa del virus de la hepatitis B en paciente que reinicia diálisis tras trasplante renal. ¿Cómo podemos prevenirlo o anticiparlo en el diagnóstico?Nefrología 2020; 40(4): 477 doi: 10.1016/j.nefro.2019.06.006
4
Mark D. Muthiah, En Ying Tan, Sin Hui Melissa Chua, Daniel Q. Y. Huang, Glenn K. Bonney, Alfred W. C. Kow, Seng Gee Lim, Yock Young Dan, Poh Seng Tan, Guan Huei Lee, Boon Leng Lim. Nucleoside analog monotherapy for prophylaxis in Hepatitis B liver transplant patients is safe and efficaciousHepatology International 2020; 14(1): 57 doi: 10.1007/s12072-019-10011-2
5
Smaragdi Marinaki, Kyriaki Kolovou, Stratigoula Sakellariou, John N Boletis, Ioanna K Delladetsima. Hepatitis B in renal transplant patientsWorld Journal of Hepatology 2017; 9(25): 1054-1063 doi: 10.4254/wjh.v9.i25.1054
6
Ivan Noreña, Mario Fernández-Ruiz, José María Aguado. Viral infections in the biologic therapy eraExpert Review of Anti-infective Therapy 2018; 16(10): 781 doi: 10.1080/14787210.2018.1521270
7
Isabel Ruiz-Camps, Juan Aguilar-Company. Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid TumorsInfectious Disease Clinics of North America 2020; 34(2): 257 doi: 10.1016/j.idc.2020.02.005
8
S. Yazaki, T. Yamauchi, T. Higashi. High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in JapanInternational Journal of Clinical Oncology 2020; 25(7): 1327 doi: 10.1007/s10147-020-01655-4
9
Seungtaek Lim, Jungwoo Han, Gun Min Kim, Kwang-Hyub Han, Hye Jin Choi. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenibJournal of Gastroenterology and Hepatology 2015; 30(6): 1024 doi: 10.1111/jgh.12898
10
Shoko Sonobe, Toru Arai, Yasushi Tanimoto, Chikatoshi Sugimoto, Masanori Kitaichi, Masanori Akira, Takahiko Kasai, Masaki Hirose, Yoshikazu Inoue. Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus CarrierInternal Medicine 2019; 58(4): 569 doi: 10.2169/internalmedicine.1329-18
11
Matthias S. Matter, Thomas Decaens, Jesper B. Andersen, Snorri S. Thorgeirsson. Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trendsJournal of Hepatology 2014; 60(4): 855 doi: 10.1016/j.jhep.2013.11.031
12
Zhuo Wang, Wei Jin, Hongchuan Jin, Xian Wang. mTOR in Viral Hepatitis and Hepatocellular Carcinoma: Function and TreatmentBioMed Research International 2014; 2014: 1 doi: 10.1155/2014/735672
13
Cheng-Shyong Chang, Chien-Yu Tsai, Sheng-Lei Yan. Hepatitis B reactivation in patients receiving targeted therapiesHematology 2017; 22(10): 592 doi: 10.1080/10245332.2017.1321882
14
M. Reinwald, J.T. Silva, N.J. Mueller, J. Fortún, C. Garzoni, J.W. de Fijter, M. Fernández-Ruiz, P. Grossi, J.M. Aguado. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)Clinical Microbiology and Infection 2018; 24: S53 doi: 10.1016/j.cmi.2018.02.009
15
C.S. Voican, O. Mir, P. Loulergue, M. Dhooge, C. Brezault, J. Dréanic, S. Chaussade, S. Pol, R. Coriat. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatmentAnnals of Oncology 2016; 27(12): 2172 doi: 10.1093/annonc/mdw414
16
Annelieke E. C. A. B. Willemsen, Filip Y. De Vos, Anne Jansen, Maaike de Boer, Vivianne C. G. Tjan-Heijnen, Carla M. L. van Herpen. Diagnostic challenges of respiratory adverse events during everolimus treatmentTargeted Oncology 2014; 9(3): 287 doi: 10.1007/s11523-014-0310-4
17
Carmine DʼAniello, Marco Maruzzo, Umberto Basso. Prevention of Hepatitis B Virus Reactivation With Lamivudine in a Patient With Advanced Renal Cell Carcinoma Treated With EverolimusAmerican Journal of Therapeutics 2016; 23(1): e300 doi: 10.1097/MJT.0000000000000005
18
Claudia Bozza, Marika Cinausero, Donatella Iacono, Fabio Puglisi. Hepatitis B and cancer: A practical guide for the oncologistCritical Reviews in Oncology/Hematology 2016; 98: 137 doi: 10.1016/j.critrevonc.2015.10.017
19
Eleonora Teplinsky, Derrick Cheung, Ilan Weisberg, Ramon E. A. Jacobs, Martin Wolff, James Park, Kent Friedman, Franco Muggia, Komal Jhaveri. Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literatureBreast Cancer Research and Treatment 2013; 141(2): 167 doi: 10.1007/s10549-013-2681-0
20
Mauro Viganò, Giuseppe Serra, Giovanni Casella, Glenda Grossi, Pietro Lampertico. Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disordersExpert Opinion on Biological Therapy 2016; 16(7): 917 doi: 10.1080/14712598.2016.1177017
21
Kirsty Wai-Chung Lee, Stephen Lam Chan. Hepatotoxicity of targeted therapy for cancerExpert Opinion on Drug Metabolism & Toxicology 2016; 12(7): 789 doi: 10.1080/17425255.2016.1190831
22
Charat Thongprayoon, Wisit Kaewput, Konika Sharma, Karn Wijarnpreecha, Napat Leeaphorn, Patompong Ungprasert, Ankit Sakhuja, Franco H Cabeza Rivera, Wisit Cheungpasitporn. Outcomes of kidney transplantation in patients with hepatitis B virus infection: A systematic review and meta-analysisWorld Journal of Hepatology 2018; 10(2): 337-346 doi: 10.4254/wjh.v10.i2.337
23
Xinying Zhou, Yijin Wang, Herold J. Metselaar, Harry L.A. Janssen, Maikel P. Peppelenbosch, Qiuwei Pan. Rapamycin and everolimus facilitate hepatitis E virus replication: Revealing a basal defense mechanism of PI3K-PKB-mTOR pathwayJournal of Hepatology 2014; 61(4): 746 doi: 10.1016/j.jhep.2014.05.026
24
Z. Liu, L. Jiang, G. Liang, E. Song, W. Jiang, Y. Zheng, C. Gong. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis managementJournal of Viral Hepatitis 2017; 24(7): 561 doi: 10.1111/jvh.12672